drug adverse effects of TNF-alpha inhibitors
Jump to navigation
Jump to search
Adverse effects
- increased risk of soft tissue & skin infection
- increased risk of intracellular baterial infection
- pulmonary & disseminated histoplasmosis, coccidioidomycosis, blastomycosis & other opportunistic infections are not consistently recognized in patients taking TNF-alpha blockers; this has resulted in delays in appropriate treatment, & death; empiric antifungal treatment indicated for suspected disseminated mycosis in patients taking TNF-alpha blocker
- increased risk of lymphoma & other cancers associated with use in children & adolescents[3]
- increased risk of melanoma in patients with rheumatoid arthritis (RR=1.5)[5]
- TNF inhibitors do not increase risk of cancer recurrence in cancer survivors[6]
- drug-induced lupus[4]
More general terms
References
- ↑ Dixon WG et al, Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum 2006, 54:2368 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16868999
Singh JA et al Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. May 11, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25975452 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961704-9/abstract
Dixon WG. Rheumatoid arthritis: Biological drugs and risk of infection. Lancet 2015 May 11 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25975453 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961907-3/abstract - ↑ FDA MedWatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#TNF2
- ↑ 3.0 3.1 FDA MedWatch Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) August 2009 http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm
- ↑ 4.0 4.1 Medical Knowledge Self Assessment Program (MKSAP) 14, American College of Physicians, Philadelphia 2006
- ↑ 5.0 5.1 Raaschou P et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: Nationwide population based prospective cohort study from Sweden. BMJ 2013 Apr 8; 346:f1939 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23568792
- ↑ 6.0 6.1 Raaschou P, Soderling J, Turesson C, Askling J; ARTIS Study Group. Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: A nationwide population-based cohort study. Ann Intern Med 2018 Sep 4; 169:291 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/30105374 <Internet> http://annals.org/aim/article-abstract/2697083/tumor-necrosis-factor-inhibitors-cancer-recurrence-swedish-patients-rheumatoid-arthritis